Ultragenyx Pharmaceutical INC Form 4 insider transactions

Karah Herdman Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., sold 1,900 shares of common stock on August 3, 2026 for $24.92 per share.

Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., sold 4,696 shares of common stock on August 3, 2026 for $24.92 per share.

Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a transaction involving the purchase of common stock.

Director Corazon D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical Inc. common stock on June 15, 2026.

EVP and Chief Legal Officer Karah Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical Inc. common stock.

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn sold 4,653 shares of common stock on June 1, 2026.

Director Matthew K. Fust acquired 7,751 restricted stock units and 14,058 stock options as part of annual compensation.

Director Shehnaaz Suliman acquired restricted stock units and stock options while selling a portion of common stock holdings.

Director Amrit Ray was granted 7,751 restricted stock units and 14,058 stock options as part of the Ultragenyx 2023 Incentive Plan.

Director Corsee Sanders was granted 7,751 restricted stock units and 14,058 stock options as part of the company's 2023 Incentive Plan.

Director Michael Narachi was granted 7,751 restricted stock units and 14,058 stock options by Ultragenyx Pharmaceutical.

Director Daniel Welch was granted 7,751 restricted stock units and 14,058 stock options as part of the company's 2023 Incentive Plan.

Director Deborah Dunsire acquired 7,751 restricted stock units and 14,058 stock options as part of an annual incentive plan.

Ultragenyx Pharmaceutical Inc. executive Eric Crombez sold company stock to cover tax obligations related to restricted stock unit vesting.

Chief Financial Officer Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical Inc. common stock on May 1, 2026.

Ultragenyx Pharmaceutical Inc. SVP and Chief Accounting Officer Theodore Huizenga was granted 20,241 restricted stock units and 7,348 stock options.

Ultragenyx Pharmaceutical CEO Emil Kakkis was granted 76,745 restricted stock units and 132,693 stock options as part of the company's 2023 incentive plan.

Dennis Karl Huang, EVP and Chief Technical Operations Officer at Ultragenyx, was granted restricted stock units and stock options as part of the company's 2023 Incentive Plan.

John Richard Pinion, EVP and Chief Quality Operations Officer at Ultragenyx, was granted 23,116 restricted stock units and 79,936 stock options.

EVP and Chief Legal Officer Karah Parschauer was granted restricted stock units and stock options as part of the company's 2023 Incentive Plan.

EVP & Chief Commercial Officer Erik Harris was granted 28,895 restricted stock units and 49,960 stock options by Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc. EVP and Chief Medical Officer Eric Crombez was granted 34,674 restricted stock units and 59,952 stock options.

Ultragenyx Pharmaceutical CFO Howard Horn was granted 34,674 restricted stock units and 59,952 stock options as part of the company's 2023 incentive plan.

Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a sale of 4,683 shares of common stock on April 1, 2026, executed under a pre-arranged 10b5-1 trading plan.

Ultragenyx Pharmaceutical Inc.'s EVP, Chief Quality Operations Officer, John Richard Pinion, reported the acquisition of shares from vested performance units and subsequent sale for tax obligations.

Ultragenyx Pharmaceutical's EVP & Chief Commercial Officer, Erik Harris, reported the acquisition of shares from performance units and subsequent sale for tax obligations.

Ultragenyx Pharmaceutical Inc.'s President & CEO, Emil D. Kakkis, reported the acquisition of shares from performance units and subsequent sale to cover tax withholdings.

Ultragenyx Pharmaceutical Inc.'s EVP and Chief Legal Officer, Karah Herdman Parschauer, sold 8,135 shares of common stock to cover tax withholdings following the conversion of performance stock units.

Ultragenyx Pharmaceutical Inc.'s SVP, Chief Accounting Officer, Theodore Alan Huizenga, disposed of shares to cover tax withholdings related to RSU vesting.

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reported the acquisition of shares from performance units and subsequent sales for tax obligations and other purposes.